Switzerland wants binding Trump commitment on gold tariffs, lobby group says
Trump on Monday said he would not impose tariffs on gold, a move welcomed by global bullion markets and which ended days of speculation that the yellow metal could be caught up in the ongoing global trade spat.
"President Trump's statement is an encouraging signal for trade stability," said Christoph Wild, president of the ASFCMP, in a statement.
"However, only a formal and binding decision will provide the certainty the gold sector and its partners require."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
8 minutes ago
- Reuters
US oil group challenges Trump plan to cut biofuel import credits
NEW YORK, Aug 14 (Reuters) - A top U.S. oil trade group on Thursday joined a chorus of complaints against a new government proposal to slash incentives for biofuel imports, testing the Trump administration's resolve to keep the policy in the upcoming months. The mounting criticism puts the White House in the position of having to side with either farmers looking to prioritize domestic supply, or refiners seeking cheaper feedstock - both groups loyal to President Donald Trump. At issue is a proposal from the Environmental Protection Agency in June that would allocate only half as many tradable renewable fuel credits to imported biofuels and biofuel feedstocks as to domestic ones. The shift, which could be finalized before the year's end, has significant implications for bio-based diesel, which relies on imports to meet federal mandates. The U.S. Renewable Fuel Standard (RFS) requires refiners to blend billions of gallons of biofuels into the fuel market, or buy credits known as RINs from those that do to demonstrate compliance with the program. The Farm Belt, specifically soybean farmers, hailed the proposed shift as a victory, arguing the RFS was always intended to boost domestic production and that countries like China were flooding the market with cheap supply. But the oil industry argues the U.S. lacks enough feedstock to meet the federal quotas without imports, tightening an already stretched domestic market and driving prices higher. "As proposed, it is unworkable and would have significant harmful effects on the overall RFS program and could place upward pressure on fuel costs," the American Petroleum Institute said in a letter to the EPA on Thursday seen by Reuters, urging the complete removal of the import proposal. The API also questioned the legality of the proposal in separate comments seen by Reuters, signaling the deep-pocketed trade group could be prepared to go to court to challenge the administration. Refiners and farm groups were earlier this year unified on bio-based diesel, with both arguing that federal quotas needed to be higher. However, the shift on imports caught both industries by surprise. Even within trade groups, sentiment around the imports proposal is divided. "There is not consensus among our members on the proposal to reduce the RIN value for fuels produced domestically from foreign feedstock," Clean Fuels Alliance America, a biodiesel group, said in comments submitted to the EPA.
Reuters
8 minutes ago
- Reuters
Oil prices stable ahead of Trump-Putin meeting in Alaska
LONDON, Aug 14 (Reuters) - Oil prices were stable on Thursday as investors weighed the potential impact of the upcoming U.S.-Russia summit on Ukraine on Russian crude flows, after U.S. President Donald Trump warned of "severe consequences" for Moscow if it does not agree to peace. Brent crude futures were up 49 cents, or 0.75%, at $66.12 a barrel by 1303 GMT, while U.S. West Texas Intermediate crude futures rose 51 cents, or 0.81%, to $63.16. Both contracts hit their lowest levels in two months on Wednesday after bearish supply guidance from the U.S. government and the International Energy Agency (IEA). Trump on Wednesday threatened "severe consequences" if Russian President Vladimir Putin does not agree to peace in Ukraine. The U.S. president did not specify what the consequences could be, but he has warned of economic sanctions if the meeting in Alaska on Friday proves fruitless. Trump has threatened to enact secondary tariffs on buyers of Russian crude, primarily China and India, if Russia continues its war in Ukraine. "The uncertainty of U.S.-Russia peace talks continues to add a bullish risk premium given Russian oil buyers could face more economic pressure," Rystad Energy said in a client note. "How (the) Ukraine-Russia crisis resolves and Russia flows change could bring some unexpected surprises." However, some analysts remained sceptical that Trump would take action that could significantly disrupt oil supplies. "Anything that causes oil prices to rise from policy such as secondary tariffs is almost an own goal against this administration, and the man from Moscow knows it," PVM analyst John Evans said. Expectations that the U.S. Federal Reserve will cut interest rates in September also propped up oil prices, as lower borrowing rates can spur economic growth and demand for oil. Traders overwhelmingly believe a cut will happen next month after U.S. consumer prices increased at a moderate pace in July. U.S. Treasury Secretary Scott Bessent said he thought an aggressive half-percentage-point cut was possible given recent weak employment numbers. Oil prices were kept in check on Wednesday as crude inventories in the U.S. unexpectedly rose by 3 million barrels in the week ending August 8, according to the U.S. Energy Information Administration on Wednesday.
Reuters
10 minutes ago
- Reuters
Schrödinger stops development of blood cancer therapy after two patient deaths
Aug 14 (Reuters) - Schrödinger (SDGR.O), opens new tab said on Thursday it has stopped the development of an experimental drug after the death of two patients with a type of blood cancer in an early-stage trial, sending its shares down nearly 17% before the bell. The company was testing the therapy, SGR-2921, in patients with high-risk myelodysplastic syndromes, a group of blood cancers in which the bone marrow doesn't produce enough healthy blood cells, and its more serious form - acute myeloid leukemia. The drug was considered to have contributed to the deaths of two AML patients in the trial, the company said. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients," Chief Medical Officer Margaret Dugan said. In pre-clinical trial, the therapy showed responses against the cancer, which suggested SGR-2921 could ultimately be used in combination with standard of care treatments, the company said. The experimental drug was designed to work by blocking CDC7, a protein that helps cancer cells repair DNA damage during replication. By inhibiting this protein, the drug causes cancer cells to accumulate fatal levels of DNA damage.
